Related Experiment Video

Updated: Sep 6, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K

SMARCA4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint

Takahiro Utsumi1, Yohei Taniguchi1, Yuri Noda2

  • 1Department of Thoracic Surgery, Kansai Medical University, Osaka, Japan.

Thoracic Cancer
|July 2, 2022
PubMed

Insights

This case study details a rare thoracic SMARCA4-deficient undifferentiated tumor, a rapidly progressing cancer. Combination immunotherapy and chemotherapy showed potential in stabilizing the disease, offering hope for improved prognosis in this challenging malignancy.

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Pathology

Background:

  • Thoracic SMARCA4-deficient undifferentiated tumors represent a newly identified, aggressive neoplasm primarily affecting the mediastinum.
  • These tumors are characterized by rapid progression and a generally poor prognosis.

Observation:

  • A case involving a patient with a history of heavy smoking presented with respiratory distress and hemoptysis.
  • Imaging revealed pleural effusion and thickening in the right thoracic cavity.
  • A pleural biopsy confirmed large tumor cells with rhabdoid cytology, negative for key markers (SMARCA4, p40, NUT, claudin-4), indicative of SMARCA4-deficient undifferentiated malignancy.

Findings:

  • The patient received a combination treatment of atezolizumab, carboplatin, and nab-paclitaxel.
  • Stable disease was achieved and maintained for 7 months post-treatment.

Implications:

  • This case suggests that a combination of atezolizumab, carboplatin, and nab-paclitaxel may be a viable treatment option for thoracic SMARCA4-deficient undifferentiated tumors.
  • Further research is warranted to establish standardized treatment protocols and improve outcomes for this rare malignancy.
Keywords:
lung neoplasmsmediastinal diseasesnon-small-cell lung carcinomapleural effusionrespiratory distress syndrome

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

655
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K